ASND•benzinga•
RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $210
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 2, 2025 by benzinga